Whole-cell bioconversion of naringenin to high added value hydroxylated compounds using Yarrowia lipolytica 2.2ab in surface and liquid cultures

• Published in: Bioprocess and biosystems engineering Vol. 43; no. 7; pp. 1219 - 1230
• Main Authors: Hernández-Guzmán, Christian, Prado-Barragán, Arely, Gimeno, Miquel, Román-Guerrero, Angélica, Rutiaga-Quiñones, Olga Miriam, Rocha Guzmán, Nuria Elizabeth, Huerta-Ochoa, Sergio
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2020; Springer Nature B.V
• Subjects: Bioactive compounds; Bioconversion; Biological activity; Biotechnology; Chemistry; Chemistry and Materials Science; Environmental Engineering/Biotechnology; Experimentation; Food Science; Industrial and Production Engineering; Industrial Chemistry/Chemical Engineering; Low concentrations; Naringenin; Research Paper; Yarrowia lipolytica; 2.2ab; Biosynthesis; Naringenin; Hydroxylation; Whole-cell bioconversion; Yarrowia lipolytica 2.2ab
• ISSN: 1615-7591; 1615-7605
• DOI: 10.1007/s00449-020-02316-6

The bioconversion process of bioactive naringenin by whole-cells of Yarrowia lipolytica 2.2ab for the production of increased value-added compounds is successfully achieved in surface and liquid cultures. This approach is an alternative to the commercial production of these bioactive compounds from vegetable sources, which are limited due to their low concentrations and the complexity of the purification processes. The experimentation rendered seven value-added compounds in both surface and liquid bioconversion cultures. Some of the compounds produced have not been previously reported as products from the bioconversion processes, such as the case of ampelopsin. Biosynthetic pathways were suggested for the naringenin bioconversion using whole-cells of Y. lipolytica 2.2ab. Finally, the extracts obtained from the naringenin bioconversion in liquid cultures showed higher percentage of inhibition of DPPH· and ABTS· radicals up to 32.88 and 2.08 times, respectively, compared to commercial naringenin.